Skip to main content
SpringerLink
Log in

Pitavastatin: a New 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Statins have proven beneficial for reducing both primary and secondary events in patients with coronary heart disease. Tight control of serum lipid parameters in these patients is recommended by the most recent clinical guidelines. Although numerous lipid-lowering treatments are available, only a small percentage of eligible patients receive therapy and fewer achieve their lipid-lowering goals. Thus it is clear that new treatment strategies to manage patients with lipid abnormalities are warranted. Pitavastatin (Lival®; Kowa Pharmaceuticals America, Montgomery, AL, USA) has been recently approved for the treatment of hypercholesterolemia and combined dyslipidemia. Pitavastatin 1–4 mg/day has shown similar low-density lipoprotein-reducing activity to other commercially available statins, including simvastatin and atorvastatin. Adverse events occurred at similar rates to other statins in clinical trials with favorable effects seen in patients with dyslipidemia and metabolic syndrome. Pharmacokinetic drug-drug interactions are minimized due to the lack of significant metabolism of pitavastatin by the cytochrome P450 enzyme system, although some drugs affect its uptake into hepatocytes and should be avoided. In addition to its higher acquisition cost, pitavastatin has not been shown to improve clinical outcomes in high-risk patient populations and thus may not be the agent of choice in many patients at this time in lieu of cheaper, clinically proven alternatives.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy. A meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:2307–2313.

    Article  PubMed  CAS  Google Scholar 

  2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvaastatin Survival Study (4S). Lancet. 1994;344:1383–1389.

    Google Scholar 

  3. Shepherd J, Blauw G, Murphy M, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623–1630.

    Article  PubMed  CAS  Google Scholar 

  4. Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular mortality and events with statin treatments. A network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:1769–1781.

    Article  PubMed  CAS  Google Scholar 

  5. Pedersen TR, Facrgeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–2445.

    Article  PubMed  CAS  Google Scholar 

  6. Cannon CP, Braunwald D, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504.

    Article  PubMed  CAS  Google Scholar 

  7. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ. 2008;178:576–584.

    Article  PubMed  Google Scholar 

  8. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.

    Article  Google Scholar 

  9. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between nonhigh-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53:316–322.

    Article  PubMed  CAS  Google Scholar 

  10. National Cholesterol Education Panel. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143–3421.

    Google Scholar 

  11. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239.

    Article  PubMed  Google Scholar 

  12. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51:1512–1524.

    Article  PubMed  Google Scholar 

  13. Armitage J. The safety of statins in clinical practice. Lancet. 2007;370:1781–1790.

    Article  PubMed  CAS  Google Scholar 

  14. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150:858–868.

    PubMed  Google Scholar 

  15. Kotseva K, Stagmo M, De Bacquer D, et al. Treatment potential for cholesterol management in patients with heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis. 2008;197:710–717.

    Article  PubMed  CAS  Google Scholar 

  16. Livalo (pitavastatin) product information. Montgomery, AL: Kowa Pharmaceuticals America, Inc.; 2010.

  17. Aoki T, Nishimura H, Nakagawa S, et al. Pharmacologic profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneim Forsch. 1997;47:904–909.

    CAS  Google Scholar 

  18. Acemoglu M, Brodbeck A, Garcia A, et al. A new and efficient synthesis of the HMG-CoA reductase inhibitor pitavastatin. Helv Chim Acta. 2007;90:1069–1081.

    Article  CAS  Google Scholar 

  19. Hayashi T, Yohote K, Saito Y, Iguchi A. Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opin Pharmacother. 2007;8;2315–2327.

    Article  PubMed  CAS  Google Scholar 

  20. Morikawa S, Umetani M, Nakagawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb. 2000;7:138–144.

    PubMed  CAS  Google Scholar 

  21. Suzuki H, Aoki T, Tamaki T, et al. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Atherosclerosis. 1999;146:259–270.

    Article  PubMed  CAS  Google Scholar 

  22. Yanagita T, Hara E, Yotsumoto H, et al. NK-104 a potent new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, enhances posttranslational catabolism of apolipoprotein B-100 and inhibits secretion of apolipoprotein B-100 and triacylglycerols from HepG2 cells. Curr Therap Res. 1999;60:423–434.

    Article  CAS  Google Scholar 

  23. Yokoyama T, Miyauchi K, Kurata T, et al. Inhibitory efficacy of pitavastatin on the early inflammatory response and neointimal thickening in a porcine coronary after stenting. Atherosclerosis. 2004;174:253–259.

    Article  PubMed  CAS  Google Scholar 

  24. Hiraoka M, Yoshida M. A novel HMG-CoA reductase inhibitor, pitavastatin inhibits IL-6-induced CRP in liver cells via ERK 1/2-dependent but not STAT3-dependent signaling transduction. Circ J. 2003;67(suppl. 1):271.

    Google Scholar 

  25. Hayashi T, Rani P, Fukatsu A, et al. A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits. Atherosclerosis. 2004;176:255–263.

    Article  PubMed  CAS  Google Scholar 

  26. Wang J, Tokoro T, Matsui K, et al. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells. Life Sci. 2005;76:2257–2268.

    Article  PubMed  CAS  Google Scholar 

  27. Maeda K, Yasunari K, Sato E, et al. Enhanced oxidative stress in neutrophils from hyperlipidemic guinea pig. Atherosclerosis. 2005;181:87–92.

    Article  PubMed  CAS  Google Scholar 

  28. Kohno M, Shinomiya K, Abe S, et al. Inhibition of migration and proliferation of rat vascular smooth muscle cells by a new HMG-CoA reductase inhibitor, pitavastatin. Hypertens Res. 2002;25:279–285.

    Article  PubMed  CAS  Google Scholar 

  29. Markle RA, Han J, Summers BD, et al. Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem. 2003;90:23–32.

    Article  PubMed  CAS  Google Scholar 

  30. Masamura K, Oida K, Kanehara H, et al. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol. 2003;23:512–517.

    Article  PubMed  CAS  Google Scholar 

  31. Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica. 2003;33:27–41.

    Article  PubMed  CAS  Google Scholar 

  32. Shimada S, Fujino H, Hojima J, et al. Uptake mechanism of pitavastatin, a new inhibitor of HMG-CoA reductase, in rat hepatocytes. Drug Metab Pharmacokinet. 2003;18:245–251.

    Article  PubMed  CAS  Google Scholar 

  33. Hirano M, Maeda K, Shitara Y, et al. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004;311:139–146.

    Article  PubMed  CAS  Google Scholar 

  34. Hasanuma T, Nakamura M, Yaji T, et al. The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine. J Clin Therap Med. 2003;19:381–389.

    Google Scholar 

  35. Lovastatin product information. Princeton, NJ: Sandoz Inc.; 2007.

  36. Lipitor (atorvastatin) product information. New York, NY: Pfizer; 2009.

  37. Crestor (rosuvastatin) product information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2010.

  38. Simvastatin product information. Dayton, NJ: Aurobindo Pharma USA, Inc.; 2008.

  39. Pravastatin product information. Sellersville, PA: Teva Pharmaceuticals USA; 2009.

  40. Lescol (fluvastatin) product information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2006.

  41. Hui CK, Cheung MY, Lau GKK, et al. Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. Br J Clin Pharmacol. 2004;59:291–297.

    Article  Google Scholar 

  42. Kajinami K, Koizumi J, Ueda K, et al. Effects of NK-104, a new hydroxymethylglutarylcoenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Am J Cardiol. 2000;85:175–183.

    Article  Google Scholar 

  43. Noji Y, Higashikata T, Inazu A, et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2002;163:157–164.

    Article  PubMed  CAS  Google Scholar 

  44. Saito Y, Yamada N, Teramoto T, et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Drug Res. 2002;52:251–255.

    CAS  Google Scholar 

  45. Koshiyama H, Taniguchi A, Tanaka K, et al. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) Investigators. J Atheroscler Thromb. 2008;15:345–350.

    Article  PubMed  CAS  Google Scholar 

  46. Saito Y, Yamada N, Teramoto T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus Pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002;132:373–379.

    Article  Google Scholar 

  47. Park S, Kang HJ, Rim SJ, et al. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clin Ther. 2005;27:1074–1082.

    Article  PubMed  CAS  Google Scholar 

  48. Yoshitomi Y, Ishii T, Kaneki M, et al. Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study. J Atheroscler Thromb. 2006;13:108–113.

    Article  PubMed  CAS  Google Scholar 

  49. Lee SH, Chung N, Kwan J, et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther. 2007;29:2365–2373.

    Article  PubMed  CAS  Google Scholar 

  50. Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients Collaborative study on Hypercholesterolemia drug Intervention and their Benefits for Atherosclerosis prevention (CHIBA study). Atherosclerosis. 2008;201:345–335.

    Article  PubMed  CAS  Google Scholar 

  51. Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther. 2008;30:1089–1101.

    Article  PubMed  CAS  Google Scholar 

  52. Budinski D, Arneson V, Hounslow N, et al. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol. 2009;4:291–302.

    Article  CAS  Google Scholar 

  53. Sansanayudh N, Wongwiwatthananukit S, Putwai P, et al. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia. Ann Pharmacother. 2010;44:507–514.

    Article  Google Scholar 

  54. Takashima H, Ozaki Y, Yasukawa T, et al. Impact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaque: a 3-dimensional intravascular ultrasound study. Circ J. 2007;71:1678–1684.

    Article  PubMed  CAS  Google Scholar 

  55. Nakamura T, Obata J, Kitta Y, et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J Cardiovasc Pharmacol. 2008;51:365–371.

    Article  PubMed  CAS  Google Scholar 

  56. Toi T, Taguchi I, Yoneda S, et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque: comparison with atorvastatin. Circ J. 2009;73:1466–1472.

    Article  PubMed  CAS  Google Scholar 

  57. Miyauchi K, Kimura T, Morimoto T, et al. Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS): rationale and design. Circ J. 2006;70:1624–1628.

    Article  PubMed  CAS  Google Scholar 

  58. Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS). J Am Coll Cardiol. 2009;54:293–302.

    Article  PubMed  Google Scholar 

  59. Sone H, Takahashi A, Shimano H, et al. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci. 2002;71:2403–2412.

    Article  PubMed  CAS  Google Scholar 

  60. Motomura T, Okamoto M, Kitamura T, et al. Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients. J Atheroscler Thromb. 2009;16:546–552.

    Article  PubMed  CAS  Google Scholar 

  61. Hiro T, Kimura T, Morimoto T, et al. Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound observations from the JAPAN-ACS trial. Circ J. 2010;72:1165–1172.

    Article  Google Scholar 

  62. Tokuno A, Hirano T, Hayashi T, et al. The effects of statin and fibrate on lowering small dense LDL-cholesterol in hyperlipidemic patients with type 2 diabetes. J Atheroscler Thromb. 2007;14:128–132.

    Article  PubMed  CAS  Google Scholar 

  63. Nomura S, Inami N, Shouzu A, et al. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets. 2009;20:16–22.

    Article  PubMed  CAS  Google Scholar 

  64. Kimura K, Shimano H, Yokote K, et al. Effects of pitavastatin (LIVALO Tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease: sub-analysis of the LIVALO Effectiveness and Safety (LIVES) study. J Atheroscler Thromb. 2010;17:601–609.

    Article  PubMed  CAS  Google Scholar 

  65. Nakamura T, Sato E, Fujiwara N, et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res. 2010;61:58–61.

    Article  PubMed  CAS  Google Scholar 

  66. Ose L, Budinski D, Hounslow N, et al. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis. 2010;210:202–208.

    Article  PubMed  CAS  Google Scholar 

  67. Kobayashi M, Chisaki I, Narumi K, et al. Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins. Life Sciences. 2008;82:969–975.

    Article  PubMed  CAS  Google Scholar 

  68. Baker WL, Talati R, White CM, et al. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010;87:98–107.

    Article  PubMed  CAS  Google Scholar 

  69. Kawai T, Tokui M, Funae O, et al. Efficacy of pitavastatin, a new HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes. Diabetes Care. 2005;28:2980–2981.

    Article  PubMed  Google Scholar 

  70. Hirano M, Maeda K, Shitara Y, et al. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Disp. 2006;34:1229–1236.

    Article  CAS  Google Scholar 

  71. Choi CI, Bae JW, Moon SM, et al. Effects of clarithromycin on the pharmacokinetics of pitavastatin. Basic Clin Pharmacol Tox. 2009;105(suppl. 1):70. Abstract MP 104.

    Google Scholar 

  72. Fujino H, Yamada I, Shimada S, et al. Interaction between fibrates and statins: metabolic interactions with gemfibrozil. Drug Metab Drug Int. 2003;19:161–176.

    Article  Google Scholar 

  73. Fujino H, Saito T, Tsunenari Y, et al. Effect of gemfibrozil on the metabolism of pitavastatin: determining the best animal model for human CYP and UGT activities. Drug Metab Drug Int. 2004;20:25–42.

    Article  CAS  Google Scholar 

  74. Mathew P, Cuddy T, Tracewell WG, et al. An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers. Clin Pharmacol Ther. 2004;75:P33. Abstract PI-115.

    Article  Google Scholar 

  75. Ando H, Tsuruoka S, Yanagihara H, et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol. 2005;60:494–497.

    Article  PubMed  CAS  Google Scholar 

  76. Mak WLV, Hu M, Yin Q, et al. Interaction of pitavastatin with grapefruit juice in subjects with different efflux transporter BRCP ABCG2 421C>A genotypes. Int J Cardiol. 2008;125(suppl. 1):S59. Abstract P 327.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Schools of Pharmacy and Medicine, University of Connecticut, 263 Farmington Ave, MC2205, Storrs and Farmington, CT, 06030, USA

    William L. Baker & Rupangi Datta

Authors
  1. William L. Baker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rupangi Datta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William L. Baker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baker, W.L., Datta, R. Pitavastatin: a New 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia. Adv Therapy 28, 13–27 (2011). https://doi.org/10.1007/s12325-010-0092-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-010-0092-8

Keywords

Search

Navigation